Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), Synergy CHC (SNYR) and Humana (HUM)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Quest Diagnostics (DGX – Research Report), Synergy CHC (SNYR – Research Report) and Humana (HUM – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Quest Diagnostics (DGX)
Quest Diagnostics received a Buy rating and a $210.00 price target from Barclays analyst Luke Sergott on January 29. The company’s shares closed last Friday at $187.03.
According to TipRanks.com, Sergott is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Quest Diagnostics with a $203.33 average price target, which is a 10.6% upside from current levels. In a report issued on January 15, TipRanks – Google also reiterated a Buy rating on the stock with a $214.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Synergy CHC (SNYR)
In a report released today, Edward Woo from Ascendiant initiated coverage with a Buy rating on Synergy CHC and a price target of $5.00. The company’s shares closed last Friday at $1.87.
According to TipRanks.com, Woo is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Synergy CHC with a $6.00 average price target.
Humana (HUM)
In a report released today, Erin Wright from Morgan Stanley downgraded Humana to Sell, with a price target of $174.00. The company’s shares closed last Friday at $195.20.
According to TipRanks.com, Wright is a 5-star analyst with an average return of
Currently, the analyst consensus on Humana is a Hold with an average price target of $279.31.
